Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Thermo Fisher opens Niche Diagnostics Center of Excellence in California

Thermo Fisher Scientific, Inc., a biotechnology product development company, has opened a new $85 million Niche Diagnostics Center of Excellence in Fremont, California.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

PURE Bioscience appoints new board member

PURE Bioscience, Inc., a developer of the patented silver dihydrogen citrate antimicrobial products, has appointed Tom Lee to its board of directors.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Merck receives breakthrough therapy designation from FDA for lung cancer drug

Merck & Co., Inc. has received breakthrough therapy designation from the FDA for KEYTRUDA, the company's anti-PD-1 therapy, for the treatment of patients with epidermal growth factor receptor, or EGFR, mutation-negative, and anaplastic lymphoma kinase, or ALK, rearrangement-negative non-small cell lung cancer, or NSCLC, whose disease has progressed on or following platinum-based chemotherapy.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Align Technology reports higher Q3 net profit, provides Q4 guidance

Align Technology, Inc., a developer of clear aligner orthodontics, has reported that net profit for the third quarter ended September 30, 2014 was $38.25 million, or $0.47 per diluted share, compared to $34.54 million, or $0.42 per diluted share, for the same quarter ended September 30, 2013. For fourth quarter of 2014, the company expects net revenues to be in the range of $194.9 million to $199.1 million and diluted EPS to be in the range of $0.47 to $0.50.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

ChenMed deploys 8x8 Virtual Office services

8x8, Inc., a provider of cloud-based unified communications, has announced that ChenMed has deployed 8x8 Virtual Office services at 36 Chen and JenCare Neighborhood Medical Centers and two corporate offices in six US states.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Edwards Lifesciences reports higher Q3 net income, provides Q4 outlook

Edwards Lifesciences Corporation, a developer of heart valve products, has reported that net income for the third quarter ended September 30, 2014 was $94.6 million, or $0.87 per diluted share, compared to $76.8 million, or $0.68 per diluted share, for the same quarter ended September 30, 2013. For fourth quarter of 2014, the company expects total sales to be between $575 million and $615 million and diluted earnings per share, excluding special items, to be between $0.89 and $0.95.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

PerkinElmer launches imaging system for cancer immunology research

PerkinElmer, Inc., a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets, has launched Mantra Quantitative Pathology Workstation with inForm Image Analysis Software for cancer immunology and immunotherapy research.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Invacare reports net loss for Q3

Invacare Corporation, a manufacturer of medical equipment, has reported that net loss for the third quarter ended September 30, 2014 were $15.1 million, or $0.47 loss per share, compared to net earnings of $16.1 million, or $0.50 per share, for the same quarter ended September 30, 2013.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Vermillion appoints COO

Vermillion, Inc., a diagnostics company focused on gynecologic cancers and women's health, has appointed Valerie Palmieri to the newly created role of COO, reporting directly to CEO James LaFrance.

Published By MarketLine
29 Oct 2014
NewsWire
NewsWire

Sigma-Aldrich Q3 net income down

Sigma-Aldrich Corporation, a developer of chemicals, biochemicals and biopharmaceutical testing services, has reported that net income for the third quarter ended September 30, 2014 was $108 million, or $0.90 per diluted share, compared to $119 million, or $0.98 per diluted share, for the same quarter ended September 30, 2013.

Published By MarketLine
29 Oct 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.